Top 5 Blue Chip Stocks To Buy For 2017

Retirement investing is not what it used to be. In the old days, one could just invest in the safe stocks to buy, in blue chips, in a nice ladder of bonds, and do just fine.

Alas, the market has significantly changed. Much of this is due to the historically low interest rates weve had.

The problem with the Federal Reserves attempt to goose the economy is that it killed bond yields, forcing retired investors further out onto the risk curve, making it difficult to find safe stocks to buy. That has pushed stock prices far higher than they should be, if one subscribes (as I do) to the Peter Lynch theory that a stocks price should reflect its net income growth rate to be added to a list of stocks to buy.

Top 5 Blue Chip Stocks To Buy For 2017: Theravance Biopharma, Inc.(TBPH)

Advisors’ Opinion:


    The exact date Theravance Biopharma Inc. (TBPH) intends to release a phase 3 update on COPD treatment Revefenacin isnt known. The company simply said in a prior communication with the market it would be sharing an interim look at the trials progress sometime in early Q4.

Top 5 Blue Chip Stocks To Buy For 2017: Firsthand Technology Value Fund, Inc.(SVVC)

Advisors’ Opinion:

  • [By Hibah Yousuf]

    Similarly, Twitter is also the biggest holding in the Firsthand Technology Value Fund (SVVC). With just over 1 million shares of the social media platform, Twitter represents nearly 11% of the total portfolio as of mid-year. Shares of Firsthand Technology Value jumped more than 6% Friday.

Top 5 Blue Chip Stocks To Buy For 2017: Just Hold Your Nose and Dive Into Under Armour Inc (UAA)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Yesterday, Under Armour (UAA) reported disappointing earnings and cut its revenue-growth forecast in half. That prompted seven analysts to cut its stock yesterday, including those at Susquehanna, Piper Jaffray, Raymond James, BofA Merrill Lynch, Wells Fargo, B. Riley, and Credit Suisse. And the downgrades have continued today, with analysts at Evercore ISI, FBR, and Canaccord Genuity joining the downgrade party.

    Getty Images

    Isn’t it a little late, now that the stock has lost a quarter of its value? Canaccord’s Camilo Lyon and Pallav Saini don’t think so:

    Following surprisingly weak Q4 results and further reduction in 2017 guidance, we are downgradingUnder Armour stock to HOLD from Buy. While EPS of 23c came in slightly below our 25c consensus estimate, sales (+12%) and gross margin (-314bps) were significantly below guidance and our expectations. The disappointing results were largely driven by weak NA apparel business, which continues to be plagued by sporting goods bankruptcies, limited lifestyle/fashion merchandise in Under Armour’s assortment, and heavy promotional activity by Nike (NKE) and Adidas to whichUnder Armour responded late. WhileUnder Armour is taking steps to rectify the assortment missteps in apparel by increasing its lifestyle offering, we are not likely to see a significant improvement before 2018. That said, there were pockets of growth within apparel, mainly golf and basketball, that underscore the value of the brand. While growth continues to be robust in footwear (+36%), international (+5 5%) and DTC (+23%), we believe the challenges in Under Armour’s NA apparel business will continue to weigh on the business in 2017. In addition, recent news reports suggest there are more sporting goods retailers (e.g. EMS, Gander Mountain, Bob’s Sports) on the verge of bankruptcy, which could put further downward pressure on athletic vendors. Lastly,Under Armour continues to invest aggressivel

  • [By Ben Levisohn]

    Hanesbrands was just one of many retail companies that got shellacked this week. Under Armour (UAA) tumbled 29% after missing earnings forecasts and cutting its guidance, while Deckers Outdoor (DECK) plunged 21% after its earnings missed the Street consensus, and Ralph Lauren (RL) plummeted 13% after its CEO stepped down.

  • [By Demitrios Kalogeropoulos]

    Meanwhile, earnings season produced large price swings in a few stocks individual stocks, including Under Armour (NYSE:UA) (NYSE:UAA) and UPS (NYSE:UPS).

  • [By Bryan Murphy]

    Under Armour Inc (NYSE:UAA) has a problem.

    In light of the 70% pullback UAA shares have suffered since the September-2015 peak, that’s not exactly news to current and would-be shareholders. Under Armour may not be in the trouble most investors might suspect it means, though. The athletic apparel outfit has deeper, philosophical problems than a failing stock. This company has developed a bad habit, and may struggle to break out of it…. IF it can break out of it.

    Giving credit where it’s due, Under Armour has never had a problem growing the top line. Leveraging sponsorships/endorsements of some (very) high profile athletes like Tom Brady, Stephen Curry, and Jordan Spieth — just to name a few — the organization has mustered double-digit sales growth for several years now. The graphic below tells the tale; click on it to view the full-screen version.

  • [By Leo Sun]

    The retail sector has been a treacherous one over the past few years, due to heavy competition from e-tailers and cutthroat competition among brick-and-mortar players. Therefore, it’s easy for investors to step on landmines across the sector if they’re not careful. Today, we’ll examine two retail stocks that could cause you to lose a lot of money — Macy’s (NYSE:M) and Under Armour (NYSE:UAA) (NYSE:UA).

  • [By Ben Levisohn]

    As well know by now, Under Armour (UAA) plunged on Tuesday after it missed earnings forecasts and cut its revenue-growth guidance in half, resulting in so many downgrades, I’ve lost count. So it’s nice to see one group of analysts–Baird’s Jonathan Komp and Benjamin Bray–urging investors stick wit the beaten-down sports-apparel company:

    Getty Images

    “Hitting the wall,” “Getting over our skis”…Even the best/well-run growth companies (including Nike in the late-1990s) often have faced periods of slowing sales, margin contraction, and/or broader uncertainty. The key questions for long-term investors are whether the brand remains in favor, and if management has the will/fortitude to turn the ship, and we answer both with a “Yes” for Under Armour. While painful to have been wrong thus far, we believe a number of factors (including valuation relative to Nike (NKE)) support sticking with Under Armour…Given that many investors viewNike as an example of the whitespace opportunity for Under Armour, we find it interesting that following the recent pullbackUnder Armour currently commands a market capitalization that is only ~10% of that of Nike, while Under Armour’s TTM revenue is ~14% of Nike’s and TTM EBITDA is ~11% of Nike’s. The last time this occurred (rel ative market cap < relative sales/profit) was around the 2009 bottom for Under Armour.

    Shares of Under Armour have tumbled 3.6% to $20.66 at 1:36 p.m. today, while Nike has slipped 0.4% to $52.79.

Top 5 Blue Chip Stocks To Buy For 2017: AMAG Pharmaceuticals, Inc.(AMAG)

Advisors’ Opinion:


    Makena is the flagship drug from AMAG Pharmaceuticals (AMAG); the drug helps reduce the risk of preterm birth.

    The company’s blood registry preserves newborn stem cells used to treat blood and immune disorders.

  • [By Lisa Levin]

    Shares of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) were down around 36 percent to $22.95. Before the open, the issue company issued FY 2017 sales that surrounded current estimates. Also, the company announced an exclusive licensing agreement with Palatin Technologies, Inc. (NYSE: PTN) for North American rights to Rekyndatm. Raymond James downgraded AMAG Pharmaceuticals from Market Perform to Underperform.

Top 5 Blue Chip Stocks To Buy For 2017: Core-Mark Holding Company Inc.(CORE)

Advisors’ Opinion:

  • [By Monica Gerson]

    Core-Mark Holding Company, Inc. (NASDAQ: CORE) is projected to report its quarterly earnings at $0.27 per share on revenue of $2.92 billion.

    Albemarle Corporation (NYSE: ALB) is estimated to post its quarterly earnings at $0.86 per share on revenue of $814.80 million.

Leave a Reply

Your email address will not be published. Required fields are marked *